Abstract
Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2-11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.
Description
Copyright © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Publisher
Oxford University Press
Date of publication
Spring 1-7-2021
Language
english
Persistent identifier
http://hdl.handle.net/10950/4572
Document Type
Article
Recommended Citation
Morrisette, Taylor; Alosaimy, Sara; Philley, Julie V.; Wadle, Carly; Howard, Catessa; Webb, Andrew J.; Veve, Michael P.; Barger, Melissa L.; Bouchard, Jeannette; Gore, Tristan W.; Lagnf., Abdalhamid M.; Ansari, Iman; Mejia-Chew, Carlos; Cohen, Keira A.; and Rybak, Michael J., "Preliminary, Real-world, Multicenter Experience with Omadacycline for Mycobacterium abscessus Infections" (2021). School of Medical and Biological Sciences Faculty Publications and Presentations. Paper 14.
http://hdl.handle.net/10950/4572